Circadian Technologies (ASX:CIR) has posted a AUD$5.8 million profit for the 2003-04 financial year, and the prospects of an even better year next year thanks to the recent acquisition of its investee company Axon Instruments by US firm Molecular Devices on July 1.

Ask Alan Finkel what he would do differently if he started another company, and he’s quick to reply. “I wouldn’t start another company overseas,” he says.

Since last year's BIO, the Australian biotechnology sector has been all about growth, writes Melissa Trudinger.

Melbourne-based Optiscan Imaging (ASX:OIL) has emerged from a quiet patch with the first results from a series of clinical studies using its flexible endomicroscopes.

Biosignal (ASX:BOS) listed today on the Australian Stock Exchange, with shares leaping to AUD$0.38, a premium of almost 100 per cent on its $0.20 issue price.

Microarray and cellular screening company Axon Instruments (ASX:AXN) has accepted a friendly takeover offer from California-based Molecular Diagnostics.

Austerity measures have borne fruit at US-based Axon Instruments (ASX:AXN) -- the company's results, announced yesterday, trumpeted a profit after tax of US$1.1 million, compared to a US$9.5 million loss in 2002.

Axon Instruments (ASX:AXN) has sold its majority shareholding in Optiscan Imaging (ASX:OIL) to JF Asset Management, the Hong Kong-based Jardine Fleming institutional investment group, one of the largest fund managers in the Asia Pacific region.

BresaGen (ASX:BGN) is likely to become a holding company with stakes in several businesses, including a new stem cell company formed by the merger of BresaGen's cell therapy division with San Diego stem cell company CyThera, CEO John Smeaton told the company's AGM yesterday.

It seems that memories are made of... cadherins. While cadherins -- cell adhesion molecules -- do not actually store memories, at the very least they have a major role in organising the basic architecture of the brain, and the dense filigree of fine neural interconnections in which memories are mysteriously stored.

Monash University researchers have solved the crystal structure of the protein suspected to be the focus of the autoimmune attack that destroys the fatty insulating sheath around neurons in the brain in multiple sclerosis (MS).